论文部分内容阅读
目的观察倍他乐克与依那普利联合治疗冠心病(心绞痛型)慢性心衰的临床疗效。方法对120例冠心病(心绞痛型)慢性心衰患者随机分为对照组和治疗组各60例,对照组予强心、利尿、抗凝、抗血小板、应用β-受体阻滞剂(倍他乐克)、改善心脏供血等治疗,治疗组在对照组治疗的基础上加用依那普利口服,观察两组治疗前后心率(HR)、左心室舒张末期直径(LVEDD)、左心射血分数(LVEF)及病死率。结果治疗组在减慢心率、缩小左心室舒张末期直径、提高左心射血分数及降低病死率方面均优于对照组(P<0.05)。结论倍他乐克与依那普利联合治疗冠心病(心绞痛型)慢性心衰有较好的疗效,值得在基层推广应用。
Objective To observe the clinical efficacy of Betaloc and Enalapril in the treatment of chronic heart failure with coronary heart disease (angina pectoris). Methods 120 patients with coronary heart disease (angina pectoris) chronic heart failure were randomly divided into control group and treatment group, 60 cases in each group. The control group was given cardiac, diuretic, anticoagulant and antiplatelet. He Leke), to improve the blood supply to the heart and other treatments. The treatment group was treated with enalapril on the basis of the control group, and the heart rate (HR), left ventricular end-diastolic diameter (LVEDD) Blood fraction (LVEF) and mortality. Results The treatment group was superior to the control group in reducing heart rate, reducing the diameter of left ventricular end-diastolic, increasing left ventricular ejection fraction and decreasing mortality (P <0.05). Conclusion Betaloc and Enalapril combined treatment of coronary heart disease (angina pectoris type) chronic heart failure has a good effect, it is worth to promote the use of grassroots.